­

Company News

Quest Diagnostics Completes Acquisition of Med Fusion and Clear Point in Texas, Forming National Precision Oncology Center of Excellence

MADISON, NJ — July 18, 2017 — Quest Diagnostics (NYSE: DGX) today announced that it has completed its previously announced acquisition of the laboratory businesses Med Fusion and Clear Point. Operating from a nearly 200,000 square foot facility in Lewisville, Texas, the two businesses form the basis for the company’s first [...]

July 21st, 2017|

Quest Diagnostics to Form Precision Oncology Center of Excellence Through Acquisition of Two Texas Laboratory Businesses to Serve Oncologists Nationwide

FOR IMMEDIATE RELEASE Quest Contacts Wendy Bost (Media): 973-520-2800 Shawn Bevec (Investors): 973-520-2900 Quest Diagnostics to Form Precision Oncology Center of Excellence Through Acquisition of Two Texas Laboratory Businesses to Serve Oncologists Nationwide Quest to acquire Lewisville, Texas-based Med Fusion and Clear Point to create a base in the southwestern [...]

June 14th, 2017|

med fusion launches an EGFR Liquid Biopsy service based on Roche EGFR mutation test

  LEWISVILLE, TX - med fusion, a Roche Molecular Center of Excellence and a leader in advanced laboratory diagnostics, is proud to announce the launch of their plasma based EGFR Liquid Biopsy service. The service utilizes Roche’s FDA-approved cobas® EGFR Mutation Test v2 to identify 42 mutations in the epidermal [...]

May 18th, 2017|

med fusion Launches HemeSEQ

Hematologic Neoplasm Profiles in Collaboration with The US Oncology Network. LEWISVILLE, TX (December 14th, 2016) – med fusion, a Texas Oncology and The US Oncology Network preferred laboratory, announced the expansion of its oncology testing services to include the new HemeSEQ portfolio of next generation sequencing (NGS) profiles. The HemeSEQ profiles [...]

December 13th, 2016|

med fusion Selects N-of-One to Provide Integrated Interpretation for med fusion’s New Hematologic Neoplasm Profiles

CONCORD, Mass., November 8, 2016 – N-of-One, Inc., a market leader in clinical interpretation with clinical trial matching for molecular tests, today announced that med fusion, a Texas Oncology and The US Oncology Network preferred laboratory, has selected N-of-One to provide integrated interpretation of med fusion’s new HemeSEQ™ profiles for AML, CLL, [...]

November 8th, 2016|

med fusion Expands Molecular Diagnostic Test Menu

Offers Oncologists Comprehensive Profiling Solutions to Optimize Therapeutic Decision-Making for Cancer Patients Lewisville, Texas, November 30, 2015 – med fusion, an integrated Molecular Center of Excellence and clinical trials service organization, announced the expansion of its molecular diagnostic testing services to include the Oncotype DX® assays which are available to [...]

November 30th, 2015|

med fusion Awarded Contract with Novation for Regional Reference Laboratory Testing

Lewisville, TX (September 21, 2015) - med fusion, an integrated Molecular Center of Excellence and clinical trials service organization, announces its supplier services agreement with Novation for Regional Reference Laboratory Testing. Novation is a leading health care services company serving members of VHA, the national health care network of not-for-profit [...]

September 22nd, 2015|

med fusion announces participation in Highmark Inc. Provider Network

Lewisville, TX (March, 2014) - med fusion, an integrated Molecular Center of Excellence (MCOE) and clinical trials service organization announces their agreement with Highmark Inc. to provide advanced diagnostic laboratory services for Highmark commercial and Medicare Advantage plans.  This agreement allows Highmark members in Pennsylvania and West Virginia access to [...]

February 15th, 2015|

med fusion announces Expansion of their Solid Tumor Profiling Powered by Next Generation Sequencing

Lewisville, TX (January 21, 2015) - med fusion, an integrated Molecular Center of Excellence laboratory and clinical trials service organization, today announced the release of its Solid Tumor Molecular Profiling testing services (SEQ) enhanced by Next Generation Sequencing (NGS) technology.  The introduction of NGS will further enable physicians to interrogate [...]

January 21st, 2015|

med fusion now a provider for Blue Cross and Blue Shield of Illinois

Lewisville, TX (January 6, 2015) - med fusion, an integrated molecular center of excellence and clinical trials service organization announces their agreement with Blue Cross and Blue Shield of Illinois (BCBSIL), to provide advanced diagnostic laboratory services to their members participating in BlueChoice and PPO plans.  This agreement assures, without [...]

January 6th, 2015|

med fusion and GenomOncology Partner to Match Drug and Clinical Trial Options to Patient Tumors

  Lewisville, TX and Cleveland, OH, (October 8, 2014) – med fusion, an integrated molecular center of excellence and clinical trials service organization and GenomOncology, an Ohio based genomics technology and services provider, today announced a partnership to optimize treatment strategies based on the patient’s disease state and tumor profile. [...]

October 8th, 2014|

Jon L. Hart Named Chief Executive Officer of med fusion

Lewisville, Texas (April 7, 2014) ― med fusion, an integrated, advanced laboratory and clinical trials service organization, announced today the appointment of Jon L. Hart as chief executive officer, effective March 31. This appointment is the next step in the organization’s continued drive towards becoming the clear leader in providing [...]

April 7th, 2014|